Prospective study on the incidence and outcome of HHV-6 encephalitis in patients who undergo allogeneic haploidentical HSCT

Study type:

Study number:

84140130

Type of Stem Cell Treatment:

Allogeneic - Haploidentical

Diseases:

Complications: infectious

Short title:

HHV6 encephalitis after HAPLO HSCT

Primary objective:

Incidence of HHV-6 CNS infection in haploidentical setting in the period 0-100 days after transplant

Key inclusion criteria:

- any age
- diagnosis of AL, MDS, Lymphoma
- HAPLO HSCT

Country:

All EBMT member countries

Principal investigator:

Katia Perruccio

EBMT Study coordinator:

Nina Knelange

Study coordinator email:

idwp@ebmt.org

EBMT Study Unit:

Leiden Study Unit

Reason for processing personal data:

Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.

Categories of personal data collected:

DOB/YOB, gender

Medical data already reported to the EBMT Registry

Study Specific Questionnaire (MED-C)

Recipients who may access the data:

Leiden Study Unit

Statistical Unit

3rd-party processors of Personal Data on behalf of EBMT/Service provider:

No

Article 6 lawful basis for processing personal data:

Article 6.1 (a) - Consent (Collection)

Article 9 basis for processing special category data:

Article 9(2) (a) - Consent (Collection)

Rights available to individuals:

Access

Is a Data Protection Impact Assessment required?:

DPIA performed for EBMT Registry (WP & NIS Studies)

Retention Schedule (if possible):

at least 5 years after the final report or first publication of study results